GLUT1 expression in high-risk prostate cancer: correlation with 18F-FDG-PET/CT and clinical outcome
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
GLUT1 expression in high-risk prostate cancer: correlation with 18F-FDG-PET/CT and clinical outcome
Authors
Keywords
-
Journal
PROSTATE CANCER AND PROSTATIC DISEASES
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-01-14
DOI
10.1038/s41391-020-0202-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Prediction of time to hormonal treatment failure in metastatic castrate-sensitive prostate cancer with 18F-FDG PET/CT
- (2019) Hossein Jadvar et al. JOURNAL OF NUCLEAR MEDICINE
- Clinical features of neuroendocrine prostate cancer
- (2019) Vincenza Conteduca et al. EUROPEAN JOURNAL OF CANCER
- Adenocarcinoma Prostate With Neuroendocrine Differentiation
- (2018) Girish Kumar Parida et al. CLINICAL NUCLEAR MEDICINE
- GLUT12 promotes prostate cancer cell growth and is regulated by androgens and CaMKK2 signaling
- (2018) Mark A White et al. ENDOCRINE-RELATED CANCER
- Glucose transporter 1 expression as a marker of prognosis in oesophageal adenocarcinoma
- (2018) Jaine K. Blayney et al. Oncotarget
- GLUT1 protects prostate cancer cells from glucose deprivation-induced oxidative stress
- (2018) Pedro Gonzalez-Menendez et al. Redox Biology
- Ovarian Cancer Relies on Glucose Transporter 1 to Fuel Glycolysis and Growth: Anti-Tumor Activity of BAY-876
- (2018) Yibao Ma et al. Cancers
- Influence of glucose transporter 1 activity inhibition on neuroblastoma in vitro
- (2018) Yan Peng et al. GENE
- The dark side of glucose transporters in prostate cancer: Are they a new feature to characterize carcinomas?
- (2017) Pedro Gonzalez-Menendez et al. INTERNATIONAL JOURNAL OF CANCER
- Differential expression and prognostic significance of GLUT1 according to histologic type of non-small-cell lung cancer and its association with volume-dependent parameters
- (2017) Young Wha Koh et al. LUNG CANCER
- Erratum: Cancer metabolism: a therapeutic perspective
- (2017) Ubaldo E. Martinez-Outschoorn et al. Nature Reviews Clinical Oncology
- GLUT1 regulates cell glycolysis and proliferation in prostate cancer
- (2017) Hengjun Xiao et al. PROSTATE
- Glucose Metabolism in the Progression of Prostate Cancer
- (2017) Francesca Cutruzzolà et al. Frontiers in Physiology
- The Metabolic Phenotype of Prostate Cancer
- (2017) Eric Eidelman et al. Frontiers in Oncology
- GLUT1 and ASCT2 as Predictors for Prognosis of Hepatocellular Carcinoma
- (2017) Hong-Wei Sun et al. PLoS One
- The Emerging Hallmarks of Cancer Metabolism
- (2016) Natalya N. Pavlova et al. Cell Metabolism
- Silibinin inhibits hypoxia-induced HIF-1α-mediated signaling, angiogenesis and lipogenesis in prostate cancer cells: In vitro evidence and in vivo functional imaging and metabolomics
- (2016) Gagan Deep et al. MOLECULAR CARCINOGENESIS
- Molecular Pathways: Targeting Cellular Energy Metabolism in Cancer via Inhibition of SLC2A1 and LDHA
- (2015) A. T. Ooi et al. CLINICAL CANCER RESEARCH
- Androgens enhance the glycolytic metabolism and lactate export in prostate cancer cells by modulating the expression of GLUT1, GLUT3, PFK, LDH and MCT4 genes
- (2015) Cátia V. Vaz et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Recent Update on Human Lactate Dehydrogenase Enzyme 5 (hLDH5) Inhibitors: A Promising Approach for Cancer Chemotherapy
- (2015) Reshma Rani et al. JOURNAL OF MEDICINAL CHEMISTRY
- Sunitinib reduces tumor hypoxia and angiogenesis, and radiosensitizes prostate cancer stem-like cells
- (2015) Roque Diaz et al. PROSTATE
- FDG-PET/CT for pre-operative staging and prognostic stratification of patients with high-grade prostate cancer at biopsy
- (2015) Jean-Mathieu Beauregard et al. CANCER IMAGING
- Utility of FDG-PET in clinical neuroendocrine prostate cancer
- (2014) Daniel E. Spratt et al. PROSTATE
- Hexokinase 2-Mediated Warburg Effect Is Required for PTEN- and p53-Deficiency-Driven Prostate Cancer Growth
- (2014) Lei Wang et al. Cell Reports
- Baseline 18F-FDG PET/CT Parameters as Imaging Biomarkers of Overall Survival in Castrate-Resistant Metastatic Prostate Cancer
- (2013) H. Jadvar et al. JOURNAL OF NUCLEAR MEDICINE
- Inhibition of Glucose Transporter 1 (GLUT1) Chemosensitized Head and Neck Cancer Cells to Cisplatin
- (2013) Yao-Dong Wang et al. TECHNOLOGY IN CANCER RESEARCH & TREATMENT
- Androgen-responsive and nonresponsive prostate cancer cells present a distinct glycolytic metabolism profile
- (2012) Cátia V. Vaz et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- A Small-Molecule Inhibitor of Glucose Transporter 1 Downregulates Glycolysis, Induces Cell-Cycle Arrest, and Inhibits Cancer Cell Growth In Vitro and In Vivo
- (2012) Y. Liu et al. MOLECULAR CANCER THERAPEUTICS
- Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme
- (2011) Amparo Wolf et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Targeting cancer metabolism: a therapeutic window opens
- (2011) Matthew G. Vander Heiden NATURE REVIEWS DRUG DISCOVERY
- Prognostic Value of Baseline [18F] Fluorodeoxyglucose Positron Emission Tomography and 99mTc-MDP Bone Scan in Progressing Metastatic Prostate Cancer
- (2010) G. S. P. Meirelles et al. CLINICAL CANCER RESEARCH
- Prostate Cancer: PET with 18F-FDG, 18F- or 11C-Acetate, and 18F- or 11C-Choline
- (2010) H. Jadvar JOURNAL OF NUCLEAR MEDICINE
- Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression
- (2010) A. Le et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A novel inhibitor of glucose uptake sensitizes cells to FAS-induced cell death
- (2008) T. E. Wood et al. MOLECULAR CANCER THERAPEUTICS
- FDG PET-CT demonstration of metastatic neuroendocrine tumor of prostate
- (2008) Yiyan Liu World Journal of Surgical Oncology
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now